Related Experiment Videos
The evaluation of metabolic function and fat redistribution in clinical trials
Abstract:
Changes in lipid and carbohydrate metabolism and in body composition associated with the most potent and effective therapies available are being reported with increasing frequency. These changes could potentially lead to increased risks of cardiovascular disease. Clinical trials set up to investigate new antiretroviral therapies need to explore the therapies' impact on these potentially serious adverse outcomes, at least in a subset of patients. The measurements that are feasible to include for all patients clearly differ from those required by a metabolic substudy. We propose the following: firstly, a minimal set of parameters that should be included in all trials; secondly, a desirable set of parameters that should be included whenever possible; and thirdly, a list of exploratory measures that should be considered. These exploratory measures are classified by the different mechanisms for changes in body composition or weight: endocrinal, cardiovascular, sterol and chemokine/cytokine pathways. Standardized instruments for evaluating patients' reports of body changes and potential methods for assessing the risk of cardiovascular disease are described. Minimum and desirable standards for methods of measurement are also proposed. The choice of parameters is based on expert clinical opinion. The experts consulted include investigators from four large ongoing clinical trials with substudies specifically designed to investigate lipid and carbohydrate metabolism and changes in body composition, together with standard parameters for measurement within individual mechanistic pathways. The parameters proposed should be kept under review as the body of knowledge about metabolic function and fat redistribution in HIV infection increases.
Insights
New antiretroviral therapies may alter lipid and carbohydrate metabolism, increasing cardiovascular disease risk. Standardized measurements are proposed for clinical trials to monitor these metabolic changes and body composition shifts in patients.
Area of Science:
- Clinical Medicine
- Pharmacology
- Metabolic Disorders
Background:
- Potent antiretroviral therapies are associated with increasing reports of altered lipid and carbohydrate metabolism and body composition.
- These metabolic changes may elevate the risk of cardiovascular disease in patients undergoing treatment.
Purpose of the Study:
- To propose standardized measurement parameters for evaluating metabolic and body composition changes in clinical trials of new antiretroviral therapies.
- To differentiate between minimal, desirable, and exploratory measurements for comprehensive assessment of treatment-related adverse outcomes.
Main Methods:
- Expert clinical opinion from investigators of four large ongoing clinical trials was consulted.
- Parameters were classified by underlying mechanisms: endocrinal, cardiovascular, sterol, and chemokine/cytokine pathways.
- Standardized instruments for patient-reported outcomes and cardiovascular risk assessment were described.
Main Results:
- A tiered approach to measurement is proposed: a minimal set for all trials, a desirable set for broader inclusion, and exploratory measures for mechanistic insights.
- Specific recommendations for assessing lipid and carbohydrate metabolism, and body composition changes are outlined.
- Standards for measurement methods are proposed to ensure consistency and comparability across trials.
Conclusions:
- Standardized monitoring of metabolic and body composition changes is crucial in antiretroviral therapy trials.
- The proposed measurement framework aims to improve the detection and understanding of treatment-related adverse events.
- Continuous review of proposed parameters is recommended as knowledge of HIV-related metabolic dysfunction evolves.